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Abstract
Sclerostin, the Wnt signaling antagonist encoded by the Sost gene, is secreted by osteocytes and
inhibits bone formation by osteoblasts. Mechanical stimulation reduces sclerostin expression,
suggesting that osteocytes might coordinate the osteogenic response to mechanical force by locally
unleashing Wnt signaling. To investigate whether sclerostin downregulation is a pre-requisite for
load-induced bone formation, we conducted experiments in transgenic mice (TG) engineered to
maintain high levels of SOST expression during mechanical loading. This was accomplished by
introducing a human SOST transgene driven by the 8kb fragment of the DMP1 promoter that also
provided osteocyte specificity of the transgene. Right ulnae were subjected to in vivo cyclic axial
loading at equivalent strains for 1 min/day at 2Hz; left ulnae served as internal controls.
Endogenous murine Sost mRNA expression measured 24h after 1 loading bout was decreased by
about 50% in TG and wild type (WT) littermates. In contrast, human SOST, only expressed in TG
mice, remained high after loading. Mice were loaded on 3 consecutive days and bone formation
was quantified 16 days after initiation of loading. Periosteal bone formation in control ulnae was
similar in WT and TG mice. Loading induced the expected strain-dependent increase in bone
formation in WT mice, resulting from increases in both mineralizing surface (MS/BS) and mineral
apposition rate (MAR). In contrast, load-induced bone formation was reduced by 70–85% in TG
mice, due to lower MS/BS and complete inhibition of MAR. Moreover, Wnt target gene
expression induced by loading in WT mice was absent in TG mice. Thus, downregulation of Sost/
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sclerostin in osteocytes is an obligatory step in the mechanotransduction cascade that activates
Wnt signaling and directs osteogenesis to where bone is structurally needed.
Keywords
Osteocytes; Sost; sclerostin; mechanical loading; bone formation; Wnt signaling
Introduction
The skeleton adapts to meet mechanical needs by changing its mass, shape, and
microarchitecture [1–3]. Osteocytes (former osteoblasts buried in the bone matrix) are
proposed to act as mechanosensors [4]. Whereas bone-forming osteoblasts and bone-
resorbing osteoclasts are present on bone surfaces for relatively short periods of time and in
low numbers, osteocytes are by far the most abundant resident cells and are present
throughout the entire bone tissue. Osteocytes are also the core of a functional syncytium that
extends from the mineralized bone matrix to the bone surface and the bone marrow,
reaching the blood vessels. Their abundance and strategic location make osteocytes the most
suitable candidates for detecting variations in the level of strain and for distributing signals
leading to adaptive responses [5].
Regulation of the expression of sclerostin, a glycoprotein encoded by the Sost gene, has
emerged as a compelling mechanism by which osteocytes control the activity of bone
remodeling cells [6]. This protein is secreted by osteocytes and acts in a paracrine (and
potentially autocrine) fashion to inhibit bone formation by antagonizing the pro-
differentiating and survival actions of Wnts in osteoblasts. Genetic and pharmacologic
evidence supports this mechanism. Loss of SOST expression in humans causes the high bone
mass disorders Van Buchem’s disease [7] and sclerosteosis [8]. Mice with targeted deletion
of the Sost gene also display progressive high bone mass and increased bone strength [9,
10]; whereas, conversely, transgenic mice overexpressing SOST exhibit low bone mass [11–
13]. Pharmacologic inhibition of sclerostin with neutralizing antibodies leads to marked
anabolic effects in several preclinical osteopenic animal models and has been met with
promising results in clinical settings [6, 14]. Sclerostin is also regulated by hormonal stimuli
that affect the skeleton. In particular, elevation of parathyroid hormone (PTH), either in an
intermittent or a continuous mode, downregulates sclerostin expression in osteocytes in mice
and decreases the circulating levels of the protein in humans [15–19].
Mechanical forces are essential for the development, growth, and maintenance of the
skeleton. Skeletal sites subjected to high mechanical strains exhibit high bone formation,
whereas unloaded bones display reduced bone formation. These adaptive responses of the
skeleton are thought to be mediated by osteocytes and to result from regulation of the Wnt
signaling pathway [4]. Using the murine ulnar loading model [20], we have demonstrated
that cortical bone areas exposed to high mechanical strain exhibit a reduction in sclerostin-
positive osteocytes that is associated with higher bone formation on adjacent periosteal
surfaces [21]. This evidence suggested that osteocytes coordinate the osteogenic response to
mechanical force by downregulating sclerostin, thereby locally unleashing Wnt signaling.
We now show that mice overexpressing a human SOST transgene in osteocytes, which is not
downregulated by loading, failed to exhibit activation of the Wnt pathway and the anabolic
response to mechanical stimulation. Thus, Sost downregulation is an obligatory step for
mechanotransduction.
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Materials and Methods
DMP1-SOST transgenic mice
DMP1-SOST transgenic mice were generated by inserting the human SOST cDNA
(I.M.A.G.E. clone ID: 40009482, American Tissue Culture Collection, Manassas, VA)
downstream from a DNA fragment containing 8 kb of the 5′-flanking region, the first exon,
the first intron, and 17 bp of exon 2 of the murine dentin matrix protein 1 (DMP1) gene [22],
and upstream from a 140 bp fragment containing the rabbit beta-globin polyadenylation
sequence, as previously described [13]. Hemizygous DMP1-SOST mice or wild type
littermates were used in the experiments. Mice were fed a regular diet (Harlan/Teklad
#7001, Indianapolis, IN) and water ad libitum and maintained on a 12-h light/dark cycle.
Protocols were approved by the Institutional Animal Care and Use Committee of Indiana
University School of Medicine.
Bone mineral density (BMD) measurement and micro-computed tomography (Micro-CT)
analysis
Four, 8, and 16 week-old mice were anesthetized via inhalation of 2.5% isoflurane (Abbott
Laboratories, Abbott Park, IL) mixed with O2 (1.5 liter/min) and BMD of the total body,
excluding the head and the tail, lumbar spine (L1-6), and femur was measured by dual
energy x-ray absorptiometry (DXA) using a PIXImus II densitometer (G.E. Medical
Systems, Madison, WI), as previously described [23]. For micro-CT analysis, bones from 6,
10, and 16 week-old mice were dissected, cleaned off soft tissue, fixed in 10% buffered
formalin, and stored in 70% ethanol until scanned at 6 micron resolution (Skyscan 1172,
SkyScan, Kontich, Belgium). Bone length was measured using a digital sliding caliper after
removing the soft tissue.
Ulna strain measurements
Strain levels at the midshaft ulna were measured in a cohort of 6 female mice at 16 weeks of
age to derive the relation between applied force and mechanical strain for both genotypes, as
previously published [24]. Briefly, the right forearm was dissected to expose the lateral
surface of the ulnar diaphysis, and a miniature (EA-015DJ-120; Vishay, Inc.) single element
strain gauge was bonded to the midshaft. The forearm was then placed in a computer-
controlled electromagnetic mechanical actuator (Bose, Eden Prairie, MN), and exposed to
cyclic axial compression using a 2-Hz haversine waveform. The peak force was
progressively increased with each cycle, and ranged from 1.2 to 2.4 N. During loading,
conditioned voltage output from the strain gauge and output from the load cell were
recorded and processed as previously described [20]. Voltage output was converted to strain
using previously described calibration procedures. From these data the force:strain relation
was derived for both genotypes individually, and low, medium, and high loads for in vivo
mechanical loading were calculated so that 2460, 2850, and 3240 µε were generated,
respectively, in both genotypes.
In vivo ulnar loading
To examine the effect of loading on bone formation, mice were loaded 1 min per day during
3 consecutive days and bones were collected after 16 days of initiation of loading to perform
dynamic histomorphometry. Previous extensive evidence had shown that this loading
regimen and timing of measurement is the optimal to detect the increased bone formation in
areas of cortical bone exposed to high mechanical strain [20, 24]. Six to 8 female mice per
group at 16 weeks of age were loaded on the right forearm for 1 min at 120 cycles/day (2
Hz) for 3 consecutive days at low, medium and high magnitude of strain, and sacrificed 16
days after initiation of loading [24]. Mice were injected with calcein (10 mg/kg) and alizarin
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red (15 mg/kg) (Sigma Chemical Co, St. Louis, MO), 10 and 3 days before sacrifice,
respectively, as previously described [23]. The left ulnae served as non-loaded internal
controls.
To examine the effect of loading on sclerostin and Wnt target gene expression, bones were
collected after a single loading bout for mRNA expression or after 2 loading bouts for
protein expression. This approach assures that data represent early changes in gene
expression induced by loading rather than changes due to alterations in bone cell
populations. We have used these time points for sample collection in our earlier publication
demonstrating changes in Sost and sclerostin expression [21]. For mRNA analysis by
quantitative PCR, ulnae were loaded once at high strain magnitude and mice were sacrificed
24 h later. Bones were snap-frozen in liquid nitrogen and stored at −80°C until RNA
isolation. For protein analyses by Western blotting and immunohistochemistry, mice were
loaded for 2 consecutive days at high strain magnitude and sacrificed 24 h after the second
loading bout. Ulnae were dissected and cleaned off soft tissue. Bones were snap-frozen in
liquid nitrogen and stored at −80°C until used for preparation of protein lysates, or fixed in
10% buffered formalin and stored in 70% ethanol at 4°C until processed for
immunohistochemistry.
Dynamic bone histomorphometry
Dynamic bone histomorphometric analysis was done as previously described [13]. Briefly,
thick (100 µm) cross-sections at the mid-diaphysis of ulnae embedded in methyl
methacrylate were prepared using a diamond embedded wire saw (Histosaw, Delaware
Diamond Knives, Wilmington, DE) and ground to a final thickness of around 40 µm. Total,
single, and double labeled perimeter, and inter-label width were measured on periosteal
surfaces using a semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image
Analysis Co., Nashville, TN) attached to a microscope equipped with an ultraviolet light
source (Nikon Optiphot 2 microscope, Melville, NY). The terminology and units used are
those recommended by the Histomorphometry Nomenclature Committee of the American
Society for Bone and Mineral Research [25].
Quantitative PCR
Total RNA was extracted from ulnar mid-diaphysis (approximately 1/3 of the bone) using
Ultraspec reagent (Biotecx Laboratories, Houston, TX) and treated with RNase-free DNase
(Promega, Madison, WI). cDNA was synthesized using high capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA). Gene expression was analyzed by
quantitative PCR using primer probe sets from Applied Biosystems or from Roche Applied
Science (Indianapolis, IN). Relative mRNA expression levels were normalized to the house-
keeping gene ribosomal protein S2 (ChoB) using the ΔCt method.
Western blotting
Protein lysates were prepared from ulnar mid-diaphysis (approximately 1/3 of the bone), as
previously described [15]. Twenty µg of protein were separated on a 10% SDS-PAGE gel
and electrotransferred to PVDF membrane (Millipore, Billerica, MA). Immunoblots were
performed using goat polyclonal anti-mouse sclerostin antibody (1:100 in 5% non fat milk,
R&D Systems, Minneapolis, MN), which recognizes both murine and human sclerostin, or
mouse monoclonal anti-α-tubulin antibody (1:2000 in 5% non-fat milk, Santa Cruz
Biotechnology, Santa Cruz, CA), followed by rabbit anti-goat or goat anti-mouse antibodies,
respectively, conjugated with horseradish peroxidase (1:2000 in 5% milk, Santa Cruz
Biotechnology). Blots were developed using enhanced chemiluminescence (Pierce
Biotechnology Inc., Rockford, IL). The intensity of the bands was quantified using NIH
ImageJ (http://rsb.info.nih.gov/ij/).
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Immunohistochemistry
Detection of sclerostin expression was performed on demineralized, paraffin embedded
sections of ulnae mid-diaphysis, as previously described [13]. Briefly, bones were
demineralized in 10% EDTA/4% phosphate buffered formalin (7:3) for 7 days at 4°C with
agitation. Five-µm thick sections were cut and mounted to glass slides. Sections were
deparaffinized, treated with 3% H2O2 to inhibit endogenous peroxidase activity, blocked
with rabbit or goat serum, and then incubated with 1:100 dilution of the goat polyclonal anti-
mouse sclerostin antibody used for Western blotting (R&D Systems, Minneapolis, MN).
Sections were then incubated with rabbit anti-goat horseradish peroxidase-conjugated
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Color was developed with a
diaminobenzidine substrate chromogen system (Dako Corp., Carpinteria, CA). Non-immune
IgGs were used as negative controls. 0.2% methyl green was used for counter stain. Sections
were observed under an Olympus BX51TRF microscope (Olympus America Inc., Center
Valley, PA) at 400× magnification. The number of sclerostin-positive osteocytes, defined as
osteocyte cell bodies exhibiting brown staining, and sclerostin-negative osteocytes, defined
as osteocyte cell bodies exhibiting methyl green staining, were quantified using the
OsteoMeasure High Resolution Digital Video System (OsteoMetrics Inc., Decatur, GA).
The percentage of sclerostin-positive cells was quantified in the medial region of the ulnae
receiving high peak strain during loading, as previously described [21].
Measurement of human and murine sclerostin
Murine and human sclerostin levels were measured using species-specific custom-made
single-plex Luminex kits (Millipore/Linco, St. Charles, MO). The standard range for the
mouse sclerostin assay was of 5 pg/ml to 20 ng/ml with a limit of detection of 10 pg/ml; and
the standard range for the human sclerostin assay was 12 pg/ml to 50 ng/ml down with a
limit of detection of 15 pg/ml. For measurements of circulating sclerostin, sera were
collected from transgenic and wild type littermate mice at 16 weeks of age before loading
and 24 hours after 1 or 2 loading bouts at high strain magnitude. For the tissue
measurements, femora and the 6th lumbar vertebrae were removed at necropsy, snap-frozen
in liquid nitrogen, and pulverized. Total protein was extracted with a digestion buffer (50
mM Tris buffer, pH 7.4, containing 0.1 M sodium chloride and 0.1% Triton X-100).
Sclerostin levels detected in protein extracts were normalized to total protein concentration
in lysates (determined by a BCA kit, Pierce Biotechnology, Inc., Rockford, IL).
Statistical Analysis
Data were analyzed using SigmaStat (SPSS Science, Chicago, IL). All values are reported as
the mean ± standard deviations (SD). Differences between wild type and transgenic mice
were evaluated using Student’s t-Test. Differences between loaded and non-loaded groups
for each genotype were evaluated by paired t-Test. A p value of 0.05 or lower was
considered statistically significant.
Results
Transgenic mice overexpressing human SOST in osteocytes (DMP1-SOST) exhibit low
bone mass in the axial skeleton, but no changes in mass or geometry of long bones
In a previous study, we showed that DMP1-SOST mice exhibit a marked decrease in BMD
in the spine with minimal if any changes in the long bones at 8 weeks of age [13]. Consistent
with these earlier findings, longitudinal analysis of a cohort of DMP1-SOST mice and
control littermates from 4 to 16 weeks of age demonstrated a progressive decrease in BMD
in the lumbar spine and total body BMD in both female and male mice (Table 1). A transient
decrease in femoral BMD was observed at 4 weeks of age in females and at 4 and 8 weeks
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of age in males. However, by 16 weeks of age femoral BMD in DMP1-SOST mice was not
different from littermate controls in either sex. No difference in body weight was found at
any age.
Micro-CT analysis showed a dramatic decrease in BV/TV, trabecular number, trabecular
thickness, and trabecular separation in cancellous bone of the spine of DMP1-SOST
compared to wild type mice at 6 and 10 weeks of age (Table 2). In contrast, no changes were
observed in tissue area, bone area, marrow area, cross-sectional thickness, or minimum
second moment of area (Imin) in cortical bone of the femoral or ulnar bones (Tables 2 and
3). Material density, which indicates the degree of bone mineralization, was not different in
either cancellous or cortical bone in DMP1-SOST mice compared to wild type littermates.
No differences in the length of femur or tibia were found between wild type and transgenic
mice (Table 3).
Loading decreased endogenous murine Sost expression, but did not alter the expression
of the human SOST transgene
Despite the lack of detectable differences in bone area, geometry, or mineralization, ulnae
from DMP1-SOST mice were more compliant to ex vivo cyclic axial loading. Thus, the same
loading force generated higher strains in DMP1-SOST mice compared to wild type
littermates (Figure 1A and B). Based on these measurements, right ulnae from wild type and
DMP1-SOST mice were subjected to in vivo loading by applying appropriate forces required
to induce equivalent strains of low, medium, and high magnitude (Figure 1C). WT mice
were loaded at 2.20 N, 2.56 N, and 2.90 N for low, medium, and high mechanical
stimulation, respectively. To generate equivalent strain in the TG mice at each load level,
1.90 N, 2.20 N, and 2.50 N were used for low, medium, and high mechanical stimulation,
respectively.
Consistent with earlier findings [21], loading decreased Sost mRNA and sclerostin protein
expression measured 24 h after 1 or 2 loading bouts at high strain, respectively, in wild type
mice (Figure 2A, B, and C). A similar decrease in murine (endogenous) Sost mRNA was
induced by loading in DMP1-SOST mice (Figure 2A). In contrast, the expression of human
SOST mRNA, which was only detectable in bones of transgenic mice, was not affected by
loading. This result demonstrates that the 8kb fragment of the DMP1 promoter is not
regulated by mechanical stimulation, unlike the endogenous DMP1 gene that is upregulated
[26]. Likewise, sclerostin expression, quantified by Western blotting using an antibody that
recognizes both murine and human sclerostin, was not decreased by loading in the
transgenic mice (Figure 2B). Loading significantly reduced the number of sclerostin-positive
osteocytes in wild type mice, but not in transgenic mice, as assessed by
immunohistochemistry using the same antibody (Figure 2C). To discriminate between the
murine and human proteins, sclerostin was quantified in serum and bone tissue using
species-specific Luminex assays. In contrast to the decrease in Sost and sclerostin expression
induced by loading in bone, circulating levels of murine sclerostin were not changed by
loading in wild type or transgenic mice of either sex (Figure 2D). Human sclerostin was not
detected in serum of transgenic mice, likely due to levels below the sensitivity of the assay.
However, detectable levels of the human protein were found in bones of transgenic mice of
both sexes at concentrations about ten times lower than the murine sclerostin (Figure 2E).
As previously shown at the mRNA level [13], the expression of endogenous murine
sclerostin protein was similar in transgenic and wild type mice. No changes in osteocyte
number or osteocyte density were found in DMP1-SOST mice compared to wild type
littermates or in either type of mice under non-loaded and loaded conditions (not shown).
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Overexpression of SOST/sclerostin in osteocytes disrupted the osteogenic response to
mechanical stimulation
To test whether the inability to downregulate the human SOST transgene affected the
osteogenic response induced by mechanical stimulation, bone formation was measured in
DMP1-SOST mice and wild type littermates subjected to ulnae loading. Bones from wild
type mice exhibited a robust and dose-responsive increase in osteogenesis as a result of
cyclic axial loading, as revealed by increased fluorochrome incorporation on the periosteal
surface (Figure 3A). However, fluorochrome incorporation in loaded arms from transgenic
mice was not significantly different from the contralateral (non-loaded) control limb.
Quantification of bone formation indices in non-loaded ulnae showed no differences
between wild type and transgenic mice in basal mineralizing surface per bone surface (MS/
BS), mineral apposition rate (MAR), or the resulting bone formation rate per bone surface
(BFR/BS) (Figure 3B). In wild type mice, loading induced the expected strain-dependent
increase in MS/BS and MAR, representing the surface covered by osteoblasts and the work
of osteoblasts, respectively. This resulted in a marked increase in BFR/BS. In contrast, load-
induced MS/BS was greatly reduced, and the increase in MAR was abolished in transgenic
mice, resulting in a dramatic blunting in BFR/BS with only a minimal increase induced by
high strain loading (Figure 3B). Overexpression of human SOST in osteocytes caused a 70–
85% reduction in relative BFR, calculated as BFR/BS in the loaded ulnae minus BFR/BS in
the control non-loaded ulnae per unit strain, compared to wild type mice (Figure 3C). This
demonstrates that bones from transgenic mice exhibit an overall reduced sensitivity to
mechanical loading.
Overexpression of SOST/sclerostin in osteocytes suppressed the activation of Wnt
signaling induced by mechanical stimulation
As expected, loading increased mRNA transcripts of several genes associated with
activation of Wnt signaling [23, 27], measured 24 h after 1 loading bout at high strain in
wild type mice (Figure 4A). However, the effect of loading on Wnt target gene expression
was absent in DMP1-SOST transgenic mice. Consistent with the antagonism of the Wnt
signaling pathway attributed to sclerostin, basal levels of some of the Wnt target genes, i.e.
BMP4, Smad6, naked2, and connexin 43, were significantly decreased in bones of
transgenic mice compared to wild type littermates.
Moreover, loading increased the expression of Osterix and collagen1a1 in wild type mice
(Figure 4B). In addition, it increased Runx2 and osteocalcin; and, although changes were not
statistically significant by paired t-Test, they were close to become significant or reached
significance, respectively, by Student t-Test. In contrast, loading did not significantly affect
the expression of these genes in DMP1-SOST transgenic mice. Furthermore, DMP1-SOST
mice exhibit increased basal levels of Runx2 and Osterix, as well as the early osteoblast
marker collagen1a1, suggesting a potential interference with the late stages of osteoblast
differentiation by sclerostin.
Discussion
Although it has been long recognized that mechanical loading stimulates new bone
formation on surfaces adjacent to areas to which strain is applied [20, 28], the cellular and
molecular mechanism(s) responsible for this phenomenon still remains unclear. Earlier
studies demonstrated that loading reduces the expression of sclerostin, the bone formation
inhibitor encoded by the Sost gene, in osteocytes located close to high bone formation
surfaces [21], and that activation of the Wnt pathway is one of the earliest responses of bone
to mechanical stimulation [27, 29]. Based on this previous evidence, we investigated here
whether downregulation of sclerostin expression in osteocytes was a prerequisite for
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osteogenesis induced by mechanical stimulation. Using a mouse model in which the human
SOST is expressed in osteocytes and is not regulated by loading, we provide conclusive
evidence that reduction of sclerostin is necessary for stimulation of the expression of Wnt
target genes and the increase in bone formation induced by mechanical force.
The mechanism by which sclerostin inhibits bone formation is not completely understood.
The current knowledge indicates that sclerostin binds to LRP6 and LRP5, transmembrane
proteins that together with frizzled receptors mediate the actions of Wnts [30, 31]. This
event, in turn, interferes with signaling downstream of the receptors, thereby antagonizing
the pro-differentiating and survival effects of Wnts on cells of the osteoblastic lineage [32,
33]. Consistent with previously reported Sost overexpressing mice [11, 12], DMP1-SOST
mice exhibit a stronger osteopenic phenotype in the axial compared to the appendicular
skeleton. This difference might be due to a higher impact of overexpressing SOST and
reducing Wnt signaling in cancellous bone, which exhibits higher remodeling rate than
cortical bone and is the major contributor to bone mass in the spine. In spite of lack of a
basal phenotype in the long bones, the response to loading in the ulnae was markedly
reduced in DMP1-SOST mice. Moreover, the relatively small increases in human transgenic
sclerostin levels were sufficient to abrogate the anabolic response, even if they apparently do
not fully compensate for the reduction in the endogenous protein induced by loading. These
findings suggest that there is a threshold of sclerostin above which bone formation is
inhibited, rather than a linear relationship between sclerostin and bone formation.
Similar to our findings with the DMP1-SOST transgenic mice, the response to mechanical
loading is greatly reduced in mice with germ line deletion of LRP5 [24]. Thus, either
overexpression of the Wnt antagonist sclerostin in bone or absence of the LRP5 Wnt co-
receptor gene dampens the anabolic response to mechanical force. Recent evidence has
challenged the role of LRP5 function in bone cells by proposing that LRP5 signaling
increases bone formation through inhibition of serotonin synthesis in the duodenum [34].
However, a more recent report failed to detect an association between bone formation
directed by LRP5 signaling and systemic effects mediated by serotonin. Rather, LRP5 was
found to function in bone (particularly, in osteocytes) to regulate bone mass [35]. Our
findings demonstrating that loading decreases sclerostin expression in bone without
affecting circulating levels of the protein in wild type mice argue against an extra-skeletal
effect of mechanical loading through sclerostin. Moreover, human sclerostin is only detected
in bone but not in serum of DMP1-SOST transgenic mice, likely due to its ~10-times lower
expression in bone compared to the murine endogenous protein, suggesting that human
sclerostin does not reach the circulation at high enough levels to potentially induce a
systemic response in other tissues. In particular, we have shown that DMP1-SOST mice do
not exhibit higher intestinal levels of expression of Tph1 [13], the enzyme that controls
serotonin synthesis, as would be expected if sclerostin would have interfered with LRP5
signaling in the gut. Thus, the inability of loading to increase bone formation in DMP1-
SOST mice can be attributed solely to the local increase in human sclerostin that is not
down-regulated by mechanical force.
Systemic elevation of PTH also decreases sclerostin expression [15, 16], and transgenic
mice expressing a constitutively active PTH receptor specifically in osteocytes (DMP1-
caPTHR1 mice) exhibit reduced sclerostin levels [13, 23]. Moreover, the elevated rate of
periosteal bone formation in these mice is prevented in double transgenic mice also
expressing the human SOST gene in osteocytes (DMP1-caPTHR1;DMP1-SOST mice) [13].
Taken together with the current findings, this evidence indicates that hormonal and
mechanical stimuli converge in downregulation of sclerostin expression, leading to either
systemic or local regulation of bone formation.
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The process of mechanotransduction is complex and likely results from concerted
contributions of diverse molecular cascades activated by mechanical stimuli in bone cells.
Consistent with this notion, altered responses to loading are exhibited by mice with
ubiquitous or osteoblast/osteocyte-specific deletion of genes involved in different signaling
pathways, including LRP5 [24, 36], the estrogen receptors α and β [37, 38], purinergic
receptor P2X7 [39], polycystin-1 [40] and connexin 43 [41]. The defective response to
loading in these models could be due to a failure of the osteocytes to sense mechanical
stimuli that reach the bone or to transmit signals leading to increase bone formation; or to an
impaired synthetic activity of the osteoblasts. The current studies demonstrate that
precluding osteocytes from transmitting mechanical signals through downregulation of
sclerostin results in failure of osteoblasts to respond to loading by increasing Wnt signaling
and enhancing bone formation. Thus, mechanotransduction necessitates local regulation of
Wnt signaling directed by osteocytes.
Research highlights
• The osteocyte network might detect variations in the level of mechanical strain
and distribute signals leading to adaptive responses.
• Loading downregulates the bone formation inhibitor and Wnt antagonist Sost/
sclerostin in osteocytes adjacent to high bone formation surfaces.
• We used DMP1-8kb-SOST mice, in which human SOST is expressed in
osteocytes and it is not decreased by loading.
• Maintaining high sclerostin expression in DMP1-8kb-SOST mice prevented
Wnt activation and the increase in bone formation induced by loading.
• Thus, mechanotransduction necessitates sclerostin reduction in osteocytes to
direct Wnt signaling and osteogenesis to where bone is needed.
Abbreviations
DMP1 dentin matrix protein 1
PTHrP PTH related protein
BMP bone morphogenetic protein
Cx43 connexin 43
WT wild type
TG transgenic mice
ChoB ribosomal protein S2
LRP low density lipoprotein receptor-related protein
Tph1 Tryptophan hydroxylase 1
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Figure 1. DMP1-SOST mice exhibit less resistance to mechanical loading
A. Ex vivo strain measurements were performed at the medial surface of the ulnar midshaft
from WT and TG mice. TG mice exhibited greater deformation per unit force than their WT
counterparts. Bars represent means ± SD, n=6. * indicates p<0.05 versus WT mice by
Student’s t-Test. B. Linear relation between applied peak force and mechanical strain in the
midshaft ulna from WT and TG mice. C. Loading forces applied to achieve equivalent low,
medium, and high magnitude of strain in WT and TG ulnae are shown.
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Figure 2. Loading decreases endogenous murine Sost expression, but does not alter the
expression of the human SOST transgene in bone
A Sost mRNA expression in ulnae from WT and TG mice loaded at high magnitude strain
was normalized to ChoB expression. Values are expressed as percentage of non-loaded
ulnae for each genotype. n=3. B. Sclerostin expression in protein extracts from control and
loaded ulnae of WT and TG mice was measured by Western blotting using an antibody that
recognizes murine and human sclerostin. Representative images of one mouse per genotype
are shown. Sclerostin expression was normalized to α-tubulin. n=3. C. Bone sections were
stained with the same antibody used in the Western blot analysis. Representative images of
one mouse per genotype are shown. Bars indicate 20 µm. Osteocytes expressing sclerostin
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were enumerated in the medial region of the ulnae. Results are expressed as percent of the
total number of osteocytes. n=3. D and E. Murine and human sclerostin protein levels were
measured in the sera or bones (femur and the 6th lumbar vertebra, L6) from WT and TG
mice. n= 5–9 per group. Bars represent means ± SD. ND, not detected. * indicates p<0.05
versus non-loaded ulnae of the corresponding genotype by paired t-Test.
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Figure 3. SOST overexpression in osteocytes markedly impairs the osteogenic response to
loading
A. Representative images from the medial ulnar cortex of WT and TG mice that underwent
high-magnitude loading. Note the extensive fluorochrome labeling and large interlabel width
in the loaded ulna from the WT mouse, contrasted with the weak labeling and minimal
(barely detectable) interlabel width in the loaded ulna from the TG mouse. B. Bone
histomorphometric measurements were performed on control and loaded ulnae at low,
medium, and high magnitude of strain. MS/BS, percent mineralizing bone surface per bone
surface; MAR, mineral apposition rate; BFR/BS, bone formation rate per bone surface. Bars
represent means ± SD, n=6–8. *p<0.05 versus non-loaded ulnae of the corresponding
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genotype, by paired t-Test. C. Relative bone formation rate, BFR/BS of loaded minus non-
loaded ulnae for each mouse at each strain magnitude. Means and SD are shown. n=6–8. *
indicates p<0.05 versus TG mice by Student’s t-Test.
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Figure 4. SOST overexpression in osteocytes inhibits basal and load-induced activation of Wnt
signaling
Wnt target genes and osteoblast markers were measured by quantitative PCR and
normalized to ChoB expression, in control and loaded ulnae of WT and TG mice. Bars
represent means ± SD, n=3. * indicates p<0.05 versus the corresponding non-loaded mice by
paired t-Test. # indicates p<0.05 versus non-loaded WT mice by Student’s t-Test. P values
indicated for Runx2 and OCN correspond to Student’s t-Test analysis.
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